Lucence Diagnostics founded in March 2016, is a genomic medicine company focused on personalizing cancer care. We invent novel liquid biopsy tests for cancer detection and treatment. We target common cancers in Asia, such as cancers of the lung, breast, colon, liver and nasopharyngeal. We deliver our clinical services worldwide through an ISO 15189:2012 accredited laboratory.

Lucence proprietary AmpliMARK technology powers our flagship liquid biopsy test LiquidHALLMARK®, the world first blood test that detects both cancer-causing genes and viruses in order to match patients to the best treatment. AmpliMARK is an amplicon-based sequencing technology with sensitivity and specificity of up to 99.9%. We invented this technology to detect cancer signals in blood with higher accuracy by signal amplification.

Our technology detects genomic alterations in the cancer, including somatic mutations, microsatellite instability (MSI) and viral DNA, from circulating tumor DNA (ctDNA) in blood. It is combined with our AI-powered clinical analytics engine SunTzu.AI to maximize treatment options for the patient. The improved accuracy and sensitivity of cancer detection by amplification will be a key foundation of early detection. We are now developing a test for detecting multiple cancers at the early stage towards our vision of a world with zero avoidable cancer deaths.

We are a venture-backed company with the mission to fight cancer through earlier diagnosis and treatment. We are supported by a group of like-minded investors that understands how great technology is nurtured and developed, the positive impact it can have on lives, and the real difference it can make to humanity.



We partner with healthcare providers and medical laboratories to deliver our cancer diagnostic services to physicians. We also collaborate with hospitals, research institutes and universities to conduct studies that advance the field of genomic medicine.